key: cord-0957522-u7qwitq4 authors: Korukluoglu, Gulay; Kolukirik, Mustafa; Bayrakdar, Fatma; Ozgumus, Gozde Girgin; Altas, Ayse Basak; Cosgun, Yasemin; Ketre Kolukirik, Canan Zohre title: 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations date: 2021-01-26 journal: bioRxiv DOI: 10.1101/2021.01.26.428302 sha: 86e918196872dffbb220253afb69ffd6755774d0 doc_id: 957522 cord_uid: u7qwitq4 A one-step reverse transcription and real-time PCR (RT-qPCR) test was developed for rapid screening (40 minutes) of the Spike N501Y and HV69-70del mutations in SARS-CoV-2 positive samples. The test also targets a conserved region of SARS-CoV-2 Orf1ab as an internal control. The samples containing both the N501Y and HV69-70del mutations are concluded as VOC-202012/01 positive. Samples suspected to be positive for B.1.351 or P.1 are the N501Y positive and HV69-70del negative cases. Limit of detection (LOD) of the kit for Orf1ab target is 500 copies/mL, while that of the N501, Y501 and HV69-70del targets are 5000 copies/mL. The developed assay was applied to 165 clinical samples containing SARS-CoV-2 from 32 different lineages. The SARS-CoV-2 lineages were determined via the next-generation sequencing (NGS). The RT-qPCR results were in 100% agreement with the NGS results that 19 samples were N501Y and HV69-70del positive, 10 samples were N501Y positive and HV69-70del negative, 1 sample was N501Y negative and HV69-70del positive, and 135 samples were N501Y and HV69-70del negative. All the VOC-202012/01 positive samples were detected in people who have traveled from England to Turkey. The RT-qPCR test and the Sanger sequencing was further applied to 1000 SARS-CoV-2 positive clinical samples collected in Jan2021 from the 81 different provinces of Turkey. The RT-qPCR results were in 100% agreement with the Sanger sequencing results that 32 samples were N501Y positive and HV69-70del negative, 4 samples were N501Y negative and HV69-70del positive, 964 samples were N501Y and HV69-70del negative. The specificity of the 40 minutes RT-qPCR assay relative to the sequencing-based technologies is 100%. The developed assay is an advantageous tool for timely and representative estimation of the N501Y positive variants’ prevalence because it allows testing a much higher portion of the SARS-CoV-2 positives in much lower time compared to the sequencing-based technologies. Increasing prevalence of the spike (S) N501Y mutation containing SARS-CoV-2 variants (Table 1) have significantly raised the concerns about the higher transmission rate (1) and the escape from neutralizing antibodies (2) . VOC-202012/01 is correlated with a significant increase in the rate of COVID-19 infection in the United Kingdom (3) . VOC-202012/01 could be up to 70% more transmissible than previous variants due to unusually large number of mutations in a single cluster, particularly in the S protein. A confirmed case of reinfection with SARS-CoV-2 with the second episode due to VOC-202012/01 was reported in the UK (4). The N501Y is of particular importance among the other mutations of VOC-202012/01 (3) . Mutations in Cterminal domain (CTD) (aa 333-527) of the S protein's receptor-binding domain (RBD) is most likely to change receptor recognition properties of SARS-CoV-2 (6) . N501Y sits in the receptor-binding motif and has been identified as increasing binding affinity to human ACE2 (7, 8) . Spike HV69-70del mutation of VOC-202012/01 is in the N terminal domain (NTD), has been identified in variants associated with immune escape in immunocompromised patients, and is responsible for a "dropout" in the S gene PCR target in a three-target (N, ORF1ab, S) commercial assay (3) . 77% of the sequenced SARS-CoV-2 genomes containing HV69-70del is VOC-202012/01 (5) . Therefore, screening only HV69-70del will not be decisive in regions where the VOC-202012/01 prevalence is low. The co-presence of N501Y and HV69-70del is a case only for VOC-202012/01 (5) and can be used for the monitoring regardless of the variant's prevalence. In addition, the N501Y positive and HV69-70del negative cases are the possible candidates of infections with the variants 501Y.V2 or P.1 (Table 1 ). In addition to the N501Y mutation, the 501Y.V2 and P.1 variants carry the S E484K and K417(T/N) mutations in the CTD of RBD. 9 of the 25,895 available VOC-202012/01 genomes contain the E484K mutation (5) . Escape from neutralizing antibodies by the spike protein E484K variants was previously reported using a recombinant chimeric SARS-CoV-2 reporter virus (2) . Molecular dynamic simulations have pointed out the possibility that the combination of E484K, K417N and N501Y mutations induces conformational change greater than N501Y mutant alone (9, 10) . Because all SARS-CoV-2 variants containing the N501Y are important for epidemiology, the timely and representative estimation of their prevalence by testing a much higher portion of the SARS-CoV-2 positives in much lower time compared to the sequencing-based technologies is necessary. In this study, a one-step reverse transcription and real-time PCR (RT-qPCR) test was developed for rapid screening of the Spike N501Y and HV69-70del mutations in SARS-CoV-2 positive samples. The assay consumables were produced as a ready-to-use kit by Bioeksen R&D Technologies Limited, Turkey ( Table 2 ). The N501Y detection with the kit is performed by comparing two different RT-qPCR reactions prepared using the "N501 Oligo Mix" and the "Y501 Oligo Mix". A conserved region of ORF1ab is targeted in both reactions as an internal control. SARS-CoV-2 S protein mutation HV69-70del is also targeted in both reactions to differentiate VOC-202012/01 from the other N501Y containing variants (Table 1 ). The N501Y mutation detection is made by comparing the Cq value differences in the two reactions. The "Y501 Oligo Mix" must amplify Spike-501-target better (with lower Cq values) than the "N501 Oligo Mix" does to obtain the positive N501Y mutation result. The SARS-CoV-2 genomes used for the oligonucleotide design (Table 3 ) reflect all the major lineages and the important variants emerged recently (11) . The oligonucleotide sequences in Table 2 matches 100% with all their targets in Table 3 . The oligonucleotide binding regions were also checked via CoV-GLUE in terms of the replacements, insertions and deletions (12) . Regardless of the technology used for the nucleic acid (NA) extraction, the Bio-Speedy® SARS-CoV-2 N501Y Mutation Detection Kit is applied to NA extracts previously shown to be RT-qPCR positive for SARS-CoV-2 with a threshold cycle (Cq) less than 32. Orf1ab target in the kit ensures that the NA extract kept its integrity during its storage at the temperature recommended by manufacturer of the NA extraction kit. The NA templates with Cq values more than 32 for the Orf1ab target may result in false-negative results since the LOD of the Spike-501 targeted oligo sets are 10x worse than that of the Orf1ab target. The NA extracts must be transferred in dry ice. The qPCR instruments and their software validated with the Bio-Speedy® SARS-CoV-2 N501Y Mutation Detection Kit is given in Table 4 . The details of the reaction set-up and the qPCR program is given in Table 5 . The recommended threshold level to calculate the number of threshold cycles (Cq) is 200 RFU for Insta Q96® Plus and CFX96 Touch™ instruments. The threshold level is 0.05 for Roche LightCycler® 96. "Dynamic Tube" should be active, "Slope Correct" should be passive, "Outlier Removal" should be "0", and the threshold level should be set to 0.02 to calculate the Cq values in Rotor-Gene® Q. For BMS MIC qPCR, "Non-Assay Green/Parameters/Fixed Length" options should be selected, auto-threshold setting should be active. Table 5 . Reaction set-up and the details of the qPCR program The shape of the amplification curves should be examined. If a Cq value is assigned to a sample by the instruments' software and the curve is sigmoidal, the Cq value can be used in the final evaluation. Nonsigmoidal curves should be recorded as negative. If a Cq value is assigned to a sample, but the curve is not sigmoidal, the result should be recorded as negative. On the web page linked with the QR code, examples of the sigmoidal amplification curves are given. The results obtained with the Bio-Speedy® SARS-CoV-2 N501Y Mutation Detection Kit should not be interpreted without examining these samples. If the IC does not perform as described in Table 6 , repeat the analysis by increasing the reaction volume to 50 µL by keeping the ratios of the reaction components in Table 5 . If the problem continues, then conclude as an invalid PCR template. If the IC perform as described in Table 6 , but there is no amplification in both the N501 and Y501 reactions, repeat the analysis by decreasing the annealing temperature from 60 °C to 55 °C during the 40 cycles of the amplification step ( There is a single nucleotide difference between the S-501-target of the N501 and Y501 oligo mixes. Hence, the "Y501 Oligo Mix" must amplify Spike-501-target better (with lower Cq values) than the "N501 Oligo Mix" does to obtain the positive N501Y mutation result. The differentiation is made by calculating the Cq value difference between the FAM and ROX channels for each reaction, and by comparing the Cq value differences in the two reactions. Cq difference between Y501 (FAM) and Orf1ab (ROX) channels in "Y501 Oligo Mix" reaction must be at least 1 Cq lower than that of the "N501 Oligo Mix" reaction to report N501Y mutation positivity. HV6970del mutation is positive if there is a sigmoidal curve in the (CY5) channel and the Cq is lower than 38. The calculation method is given below. On the web page linked with the QR code, an excel document that allows the calculation by entering the Cq values is provided. LOD studies determine the lowest detectable concentration of the analyte at which greater or equal to 95% of all (true positive) replicates test positive. A pool of nasopharyngeal, oropharyngeal, and nasal swab samples in Bio-Speedy® vNAT TM Transfer Tube (Cat No: BS-NA-513) that were RT-qPCR negative for SARS-CoV-2 were spiked with a cultured SARS-CoV-2 isolate given in Table 9 . Because the vNAT TM buffer lyses SARS-CoV-2 and preserves RNA, the lysate in the vNAT TM Transfer Tube was directly used in RT-qPCR reactions. The cultured virus was quantified in copies/mL by a molecular assay using 10 3 -10 6 copies/mL dilutions of synthetic SARS-CoV-2 ORF1ab gene partial synthetic RNA (Oligo-X Biotechnology, Turkey). The acceptance criteria for the dilution series to be used in the standard curves was r 2 >0.9, 1.9